Abbott Profit Tops Estimates on Emerging-Market Drug Sales

Updated on

Abbott Laboratories, the largest maker of heart stents and adult nutritional beverages, reported second-quarter profit that topped analyst estimates on surging demand for its brand-name generic drugs in developing markets.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.